On November 4, 2021 ArsenalBio, a privately held programmable cell therapy company focused on building advanced CAR T therapies for solid tumors, reported that it will present pre-clinical data from AB-X, the company’s integrated circuit T cell therapy program for the treatment of ovarian cancer (OC), at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting taking place November 10-14, 2021 in Washington D.C., and virtually (Press release, Arsenal Bio, NOV 4, 2021, View Source [SID1234594521]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The accepted abstract titles are now available on the SITC (Free SITC Whitepaper) website. Details of the poster are as follows:

Title: AB-X integrated circuit T cells demonstrate improved potency, expansion, and specificity compared to unaugmented MSLN CAR T cells
Poster Number: 213
Presenter: Stephen Santoro, Ph.D., Senior Director, Program Lead, ArsenalBio
Date and Time: The ePoster will be released virtually on Friday, Nov. 12, 2021 at 7:00 a.m. ET. Full text of the abstract will be released on the SITC (Free SITC Whitepaper) website on Tuesday, Nov. 9, 2021 at 8:00 a.m. ET.

About AB-X

AB-X is ArsenalBio’s lead discovery program for ovarian cancer. In the United States, ovarian cancer ranks fifth in cancer deaths among women and accounts for more deaths than any other cancer of the female reproductive system. T cell infiltration into tumors correlates with improved survival, but existing CAR T cell therapies have demonstrated modest benefits, suggesting Arsenal’s approach could transform the treatment paradigm. AB-X leverages a dual antigen sensing logic gate approach, targeting ALPG/P and MSLN, which are co-expressed in over 70% of primary ovarian cancers, for enhanced tumor specificity and improved safety. This dual logic gate ensures that the T cell killing is only activated at the site of the tumor. In addition, AB-X is engineered to knockdown FAS and PTPN2, two critical regulators of T cell function and persistence. Knockdown of FAS and PTPN2 results in CAR T cells that are resistant to FAS-mediated apoptosis, demonstrate enhanced expansion in vivo and show greater efficacy compared with unaugmented MSLN CAR T cells. As such, AB-X integrated circuit T cells are expected to be more specific and more potent than conventional CAR T cell approaches. We intend to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for AB-X in 2022.